Hansa Biopharma reported its Q4 2024 earnings, revealing a larger-than-expected loss and lower-than-forecast revenue. The company posted an EPS of -4.08, significantly missing the forecast of -1.98, ...
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...